Ignite Creation Date:
2024-05-06 @ 4:04 PM
Last Modification Date:
2024-10-26 @ 2:03 PM
Study NCT ID:
NCT04867707
Status:
COMPLETED
Last Update Posted:
2023-07-05
First Post:
2021-04-27
Brief Title:
Role of Neuraminidase Activity on Endothelial Dysfunction in Type 2 Diabetes
Sponsor:
University of Missouri-Columbia
Organization:
University of Missouri-Columbia
Study Overview
Official Title:
Role of Neuraminidase Activity on Endothelial Dysfunction in Type 2 Diabetes
Status:
COMPLETED
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
NAED
Brief Summary:
The objective is to determine if neuraminidase inhibition with zanamivir is efficacious as a therapeutic strategy to restore endothelial function in T2D patients
Detailed Description:
Twenty subjects will complete five days of treatment with zanamivir Baseline measurements will be taken before the initiation of treatment as well as after the conclusion of the treatment period ie a total of two assessment visits per subject Assessment visits will include vitals such as blood pressure heart rate fasting blood work for plasma neuraminidase activity plasma sialic acid plasma glucose and plasma insulin brachial artery FMD and glycocalyx integrity assessment via Glycocheck
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None